Nuvalent Website, Blog & Press Pages

Nuvalent Website, Blog & Press Pages - aVenture

Nuvalent - Library

nuvalent.comCrawled Oct 15, 2026

Careers & Hiring

2 pages

Careers/careers
Nuvalent offers opportunities to join its team.
Jobs/jobs

Team

1 page

Team/team
Nuvalent has assembled a team with expertise in structure-based drug discovery and oncology drug development.

Contact

1 page

Contact/contact
Contact Nuvalent for information about media, investors, and employment.

Homepage

1 page

Homepage/
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.

Coverage

5 items

GSK enters agreement to acquire Nuvalent, Inc.investors.nuvalent.com/2026-06-09-GSK-enters-agreement-to-acquire-Nuvalent,-Inc
GSK agreed to acquire Nuvalent in a USD 10.6 billion oncology transaction, adding several precision oncology assets to its oncology pipeline. The assets include programs for ROS1, ALK, and HER2-altered non-small cell lung cancer, as well as preclinical precision-medicine programs.
Jun 2026 · Nuvalent InvestorsNews article
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLCinvestors.nuvalent.com/2026-05-27-Nuvalent-Announces-Key-Program-and-Business-Updates,-Strengthening-Foundation-for-Global-Leadership-in-ROS1-and-ALK-positive-NSCLC
Nuvalent reports that the FDA accepted its neladalkib NDA for Priority Review and set a November 27, 2026 PDUFA target action date. The company also appointed Georg Pirmin Meyer as Chief International Officer.
May 2026 · Nuvalent InvestorsNews article
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meetinginvestors.nuvalent.com/2026-05-21-Nuvalent-Highlights-Upcoming-Data-Presentations-for-Neladalkib-and-Zidesamtinib-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting
Nuvalent announces presentations at the 2026 American Society of Clinical Oncology Annual Meeting covering data for neladalkib and zidesamtinib. The presentations include pivotal ALKOVE-1 data for neladalkib in TKI-pretreated ALK-positive non-small cell lung cancer and preliminary ARROS-1 data for zidesamtinib in ROS1-positive solid tumors outside NSCLC.
May 2026 · Nuvalent InvestorsNews article
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Resultsinvestors.nuvalent.com/2026-05-07-Nuvalent-Highlights-Recent-Pipeline-Progress,-Reiterates-Key-Anticipated-Milestones,-and-Reports-First-Quarter-2026-Financial-Results
Nuvalent reports its first-quarter 2026 financial results and highlights progress across its pipeline. The company cites submission of a new drug application for neladalkib and FDA review of zidesamtinib, which has a September 18, 2026 PDUFA date; the supplied text gives no further financial details.
May 2026 · Nuvalent InvestorsNews article